Mechanism of action
Inhibits hypoxia-inducible factor prolyl hydroxylase domain (PHD), preventing HIF-1α degradation. Stabilized HIF-1α increases EPO production in kidneys and iron metabolism, enhancing erythropoiesis.
Oral HIF stabilizer for anemia of chronic kidney disease (CKD). Increases endogenous erythropoietin production by stabilizing HIF-1α, improving hemoglobin without need for ESA injections.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2025 The Doctors Platform. All Right Reserved.